Tesamorelin: Research Overview

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH) that is uniquely distinguished in the peptide research landscape by its FDA approval. Marketed as Egrifta (original formulation) and Egrifta WR (tesamorelin F8, approved 2025 for weekly reconstitution), it is the only pharmacological agent approved in the United States specifically to reduce excess visceral abdominal fat in adults living with HIV and lipodystrophy. Its approval is narrow and condition-specific, and it has not been approved for body-composition alteration in any other population.

What is Tesamorelin?

Tesamorelin is a 44-amino-acid GHRH analogue in which the native sequence is conjugated to a trans-3-hexenoic acid moiety at the N-terminus. This modification stabilises the peptide against DPP-IV cleavage, extending its half-life relative to endogenous GHRH while preserving agonist activity at the pituitary GHRH receptor. It is administered as a once-daily subcutaneous injection in its approved indication.

Tesamorelin was developed by Theratechnologies Inc. and received initial FDA approval in November 2010 under the brand name Egrifta. An updated formulation, Egrifta WR (tesamorelin F8), received FDA approval in March 2025, offering the advantage of weekly rather than daily reconstitution for patients, while reducing injection volume.

Mechanism of Action

Tesamorelin binds with high affinity to the pituitary GHRH receptor (GHRHR), a Gs-coupled GPCR. Receptor activation stimulates adenylyl cyclase, raises intracellular cyclic AMP (cAMP), and triggers Ca2+-dependent secretion of growth hormone (GH) from pituitary somatotroph cells. The downstream effect is increased hepatic production and circulating levels of insulin-like growth factor 1 (IGF-1).

Elevated GH and IGF-1 promote lipolysis in visceral adipose tissue through hormone-sensitive lipase activation, with a preferential effect on visceral fat over subcutaneous fat. This selectivity underpins its clinical application in HIV-associated visceral fat accumulation (lipohypertrophy), where visceral adipose tissue (VAT) is disproportionately expanded relative to subcutaneous compartments.

What the Research Shows

The foundational clinical evidence base for tesamorelin derives from two landmark randomised controlled trials published in the New England Journal of Medicine and related journals. Falutz et al. (2007, NEJM DOI 10.1056/NEJMoa072375; PMID 18057338) randomly assigned 412 HIV-infected patients with abdominal fat accumulation to receive tesamorelin 2 mg/day or placebo subcutaneously for 26 weeks. The primary endpoint, change in visceral adipose tissue measured by CT scan, showed a mean reduction of approximately 15–18% in the tesamorelin arm versus no significant change with placebo (p<0.001). Secondary outcomes demonstrated improvements in triglyceride levels and waist circumference. Glycaemic parameters were not significantly worsened.

A second pivotal trial by Falutz et al. (2010, PMID 20101189) examined 400 HIV-infected adults over 26 weeks with an open-label extension, confirming that VAT reduction was sustained at approximately −18% at 52 weeks and that discontinuation of tesamorelin resulted in rebound of visceral fat toward baseline levels. These two trials formed the regulatory basis for FDA approval.

Stanley et al. (JAMA 2014, PMID 24846036) conducted a 12-month randomised trial in 61 HIV-positive patients and demonstrated that tesamorelin 2 mg/day significantly reduced liver fat content (measured by MRS) by 37% versus a 7% increase in the placebo group, with concurrent VAT reduction. This study expanded the understanding of tesamorelin’s effects on hepatic lipid accumulation in the HIV population.

Post-hoc analyses (e.g., PMID 22495074) reported that VAT reduction with tesamorelin correlates with improvements in triglycerides, adiponectin, and long-term preservation of glucose homeostasis, addressing early concerns about GH-axis stimulation worsening insulin resistance.

Pharmacokinetics

Per the FDA prescribing label, tesamorelin administered as a 2 mg subcutaneous injection achieves peak plasma concentration (Cmax) approximately 0.15 hours (9 minutes) post-injection, with a mean half-life of approximately 26–38 minutes in healthy subjects and 38 minutes in HIV-infected patients. Despite the short half-life, once-daily dosing is sufficient for sustained pharmacodynamic effect because the downstream IGF-1 response — which has a half-life of several hours — integrates multiple GH pulses. Bioavailability after subcutaneous injection is approximately 4%. The trans-3-hexenoic acid modification provides partial protection from DPP-IV, but the peptide is still largely cleared by proteolytic degradation.

Common Research Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

The FDA-approved and trial-validated dose is 2 mg administered subcutaneously once daily. All pivotal trials used this dose. Some exploratory research has examined lower doses (1 mg) for potential off-label contexts, but the regulatory evidence base is exclusively at 2 mg. The approved indication is HIV-associated lipodystrophy; use in other populations remains investigational and without regulatory approval.

Storage and Handling

Per the FDA prescribing information, tesamorelin lyophilised powder should be stored refrigerated at 2–8°C (36–46°F) and protected from light. The Egrifta WR formulation, which uses a novel F8 formulation, is reconstituted once weekly rather than daily, reducing preparation burden. Once reconstituted, product should be used per label instructions and not frozen. Full storage and reconstitution details are available in the current DailyMed label.

What It Is NOT

Tesamorelin is not growth hormone (somatropin) and does not directly replace GH; it stimulates endogenous pituitary GH secretion. It is not sermorelin (unmodified GHRH(1-29), shorter half-life, no longer marketed in the US). It is not CJC-1295 with or without DAC, which are synthetic GHRH analogues with different structural modifications and no regulatory approval. It is not approved for fat loss, anti-ageing, or body-composition improvement in people without HIV-associated lipodystrophy — any such use is off-label and unsupported by pivotal trial evidence. It is not a peptide for general GHRH axis research in the same category as unapproved research peptides; it is an approved drug whose use outside its label is a medical and regulatory matter.

References

Citations below include the FDA prescribing label (DailyMed), the two NEJM-era pivotal trials by Falutz et al., and the Stanley et al. JAMA liver-fat trial. The FDA label is the authoritative source for approved indications, dosing, and safety data.